Status:
UNKNOWN
Lactate Clearance Goal-directed Therapy in Sepsis
Lead Sponsor:
Nanfang Hospital, Southern Medical University
Conditions:
Sepsis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Serum lactate level is depended on the balance between lactate production and clearance. It is seen as a sensitive indicator reflecting not only the low systemic perfusion but microcirculatory dysfunc...
Detailed Description
Sepsis remains a great challenge for clinicians, early goal-directed therapy(EGDT), referring to a number of target-achieving indicators including systemic central venous oxygen saturation(ScvO2) afte...
Eligibility Criteria
Inclusion
- Older than 17 years old.
- Primary diagnosis is sepsis, means being confirmed or suspected infection while have at least 2 points of quickSOFA(qSOFA).
- Be transferred to intensive care unit (ICU) for the first time during this hospitalization.
- Elevated lactate ≥3.0mmol/L.
Exclusion
- Acute hemorrhage uncontrolled.
- Pregnancy.
- Known liver disease - Child-Pugh classes C, acute hepatic failure, severe hepatopathy accompany with prominent portal hypertension.
- Known being in an immunosuppressive state:
- Suffering from any disease that is unrelated with sepsis that severely inhibits the immune to infection, such as: active hematological or lymphoma malignancy, or during immunosuppressive therapy, such as chemotherapy or radiotherapy.
- Known human immunodeficiency virus (HIV) serology positive.
- Known chronic kidney disease.
- Suffering from any disease that affects lactate kinetics, such as mitochondrial encephalopathy, congenital hyperlipidemia, Wernicke encephalopathy, etc. Or other probable cause of hyperlactatemia.
- Took any drugs that affect lactate kinetics within the effective time window, such as taking metformin or phenylephrine within 1 week.
- Suffering from any disease that restricts resuscitation, such as heart failure, cardiac surgery, severe heart disease etc, or suffered from a cardio-pulmonary resuscitation,.
Key Trial Info
Start Date :
August 21 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2021
Estimated Enrollment :
1128 Patients enrolled
Trial Details
Trial ID
NCT03256461
Start Date
August 21 2017
End Date
December 1 2021
Last Update
August 22 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
NanFang hospital
Guangzhou, Guangdong, China, 510515